	US 11,987,826 B2
	Nitrilase mutant and application thereof in the synthesis of an anti-epileptic drug intermediate
Yaping Xue, Zhejiang (CN); Neng Xiong, Zhejiang (CN); Peijin Lv, Zhejiang (CN); and Yuguo Zheng, Zhejiang (CN)
Assigned to ZHEJIANG UNIVERSITY OF TECHNOLOGY, Zhejiang (CN)
Appl. No. 17/604,623
Filed by ZHEJIANG UNIVERSITY OF TECHNOLOGY, Zhejiang (CN)
PCT Filed Dec. 11, 2020, PCT No. PCT/CN2020/135583 § 371(c)(1), (2) Date Oct. 18, 2021, PCT Pub. No. WO2021/147558, PCT Pub. Date Jul. 29, 2021.
Claims priority of application No. 202010071083.9 (CN), filed on Jan. 21, 2020.
Prior Publication US 2022/0177868 A1, Jun. 9, 2022
Int. Cl. C12N 9/78 (2006.01); C12P 7/40 (2006.01); C12P 7/54 (2006.01); C12P 13/00 (2006.01)

CPC C12N 9/78 (2013.01) [C12P 13/002 (2013.01); C12Y 305/05001 (2013.01)]

8 Claims

1. A nitrilase mutant, wherein the nitrilase mutant has nitrilase activity and comprises the amino acid sequence of SEQ ID NO: 2, except for the substitution T151V, the substitution C223A, or the substitutions T151V, C223A, and C250G.